Summit Therapeutics Inc (SMMT)

$5.31

+0.84

(+18.79%)▲

Market is closed - opens 7 PM, 08 May 2024

Insights on Summit Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 705.0 → 235.0K (in $), with an average increase of 99.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -14.71M → -36.56M (in $), with an average decrease of 58.2% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 229.3% return, outperforming this stock by 252.5%

Performance

  • $4.50
    $5.33
    $5.31
    downward going graph

    15.21%

    Downside

    Day's Volatility :15.49%

    Upside

    0.33%

    downward going graph
  • $1.50
    $5.31
    $5.31
    downward going graph

    71.75%

    Downside

    52 Weeks Volatility :71.75%

    Upside

    0.0%

    downward going graph

Returns

PeriodSummit Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
6.94%
-1.9%
0.0%
6 Months
144.93%
10.3%
0.0%
1 Year
130.41%
6.1%
0.8%
3 Years
-20.32%
14.0%
-22.1%

Highlights

Market Capitalization
2.5B
Book Value
$0.11
Earnings Per Share (EPS)
-0.99
PEG Ratio
0.0
Wall Street Target Price
6.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-12.79%
Return On Equity TTM
-601.85%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
705.0K
EBITDA
-88.5M
Diluted Eps TTM
-0.99
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Summit Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 22.41%

Current $5.31
Target $6.50

Technicals Summary

Sell

Neutral

Buy

Summit Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Summit Therapeutics Inc
Summit Therapeutics Inc
13.16%
144.93%
130.41%
-20.32%
29.94%
Moderna, Inc.
Moderna, Inc.
16.21%
71.19%
-7.3%
-22.97%
418.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.36%
16.51%
28.96%
90.83%
194.82%
Novo Nordisk A/s
Novo Nordisk A/s
-2.25%
22.44%
47.93%
226.66%
414.73%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.43%
6.78%
16.98%
89.06%
138.15%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Summit Therapeutics Inc
Summit Therapeutics Inc
NA
NA
0.0
0.0
-6.02
-0.13
NA
0.11
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Summit Therapeutics Inc
Summit Therapeutics Inc
Sell
$2.5B
29.94%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
418.82%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
194.82%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
414.73%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
138.15%
28.81
36.68%

Institutional Holdings

  • BlackRock Inc

    1.39%

  • Vanguard Group Inc

    1.00%

  • Geode Capital Management, LLC

    0.44%

  • State Street Corporation

    0.35%

  • Northern Trust Corp

    0.16%

  • Charles Schwab Investment Management Inc

    0.14%

Corporate Announcements

  • Summit Therapeutics Inc Earnings

    Summit Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.

Organization
Summit Therapeutics Inc
Employees
105
CEO
Mr. Robert W. Duggan
Industry
Health Technology

Discover More

FAQs